XIENCE V™ stent design and rationale

Journal of Interventional Cardiology

Volumn 22, Issue SUPPL. 1, 2009, Pages

  Ding, Nadine ^a   Pacetti, Stephen D ^a   Tang, Fuh Wei ^a   Gada, Manish ^a   Roorda, Wouter ^a  

^a ABBOTT VASCULAR   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACRYLIC ACID; COPOLYMER; DRUG CARRIER; EVEROLIMUS; POLY(VINYLIDENE FLUORIDE CO HEXAFLUOROPROPYLENE); UNCLASSIFIED DRUG;

ARTICLE; BIOCOMPATIBILITY; BLOOD COMPATIBILITY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CORONARY STENT; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG ELUTING STENT; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; IN VIVO STUDY; PRIORITY JOURNAL; XIENCE V;

EID: 65649136166     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2009.00450.x     Document Type: Article

References (20)

1. Ruygrok P, Desaga M, Van Den Branden F, et al. One year clinical follow-up on the XIENCE V Everolimus-eluting stent system in the treatment of de novo native coronary artery lesions: The SPIRIT II study. EuroIntervention 2007 3 : 315 320.
2. Stone GW, Midei M, Newman W, et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: A randomized trial. JAMA 2008 299 : 1952 1953.
3. Joner M, Nakazawa G, Finn AV, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 2008 52 : 333 342.
4. Schuler W, Sedrani R, Cotton S, et al. SDZ RAD, a new rapamycin derivative. Transplantation 1997 64 : 36 42.
5. Adamson, A. Physical Chemistry of Surfaces, 4th ed. New York : John Wiley, 1982, p352, p413.
6. Available at : http://www.fda.gov/ohrms/dockets/dailys/04/sep04/091704/ 03m-0172-sup00001-vol1.pdf
7. Eberhart RC, Clagett CP. Catheter coatings, blood flow, and biocompatibility. Semin Hematol 1991 28 (4 suppl 7 42 48 discussion 66-68.
8. Mulvihill JN, Faradji A, Oberling F, et al. Surface passivation by human albumin of plasmaperesis circuits reduces platelet accumulation and thrombus formation. Experimental and clinical studies. J Biomed Mater Res 2004 24 : 155 163. (Pubitemid 20123720)
9. Park K, Kamath KR. Surface modification of polymeric biomaterials by albumin grafting using γ-irradiation. J Appl Biomater 2004 5 : 163 173.
10. ® arterial prostheses. Biomaterials 1989 10 : 147 155. (Pubitemid 19120668)
11. Hasebe T, Yohena S, Kamijo A, et al. Fluorine doping into diamond-like carbon coatings inhibits protein adsorption and platelet activation. J Biomed Mater Res 2007 83A : 1192 1199. (Pubitemid 350231782)
12. Hasebe T, Ishimaru T, Kamijo A, et al. Effects of surface roughness on anti-thrombogenicity of diamond-like carbon films. Diamond & Related Mater 2007 16 (N4-7 1343 1348. (Pubitemid 46553852)
13. Pedrini L, Dondi M, Magagnoli A, et al. Evaluation of thrombogenicity of fluoropassivated polyester patches following carotid endarterectomy. Ann Vasc Surg 2001 15 : 679 683. (Pubitemid 33115653)
14. Guidoin R, Marois Y, Zhang Z, et al. The benefits of fluoropassivation of polyester arterial prostheses as observed in a canine model. ASAIO J 1994 40 : M870 M879. (Pubitemid 24364325)
15. Chinn JA, Sauter JA, Phillips RE, Jr., et al. Blood and tissue compatibility of modified polyester: thrombosis, inflammation, and healing. J Biomed Mater Res 1998 39 : 130 140. (Pubitemid 128751765)
16. Hasebe T, Shimada A, Suzuki T, et al. Fluorinated diamond-like carbon as antithrombogenic coating for blood-contacting devices. 2006 76a : 86 94.
17. Petersen RJ, Rozelle LT. Ethylcellulose perfluorobutyrate: A highly non-thrombogenic fluoropolymer for gas exchange membranes. Trans Am Soc Artif Intern Organs 1975 21 : 242 248.
18. Liu TY, Lin WC, Huang LY, et al. Surface characteristics and hemocompatibility of PAN/PVDF blend membranes. Polym Adv Technol 2005 16 : 413 419. (Pubitemid 40707112)
19. Karl Graffte. Fluoropolymers: Fitting the bill for medical applications. MDDI 2005 Oct : 34 37.
20. Beijk, MA, Neumann FJ, Weimer M, et al. Two-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowing (The SPIRIT FIRST Trial). EuroIntervention 2007 1 : 266 272.